Cannabis Report
Lithium
Home > Boards > US OTC > Medical - Healthcare >

Decision Diagnostics Corp. (DECN)

DECN RSS Feed
Add DECN Price Alert      Hide Sticky   Hide Intro
Moderator: nonsequetor, plutoniumimplosion
Search This Board: 
Last Post: 8/17/2018 11:09:40 AM - Followers: 224 - Board type: Free - Posts Today: 11

PetSure!



http://www.pharmatechsolutions.co/assets/images/petsurepowerpoint.pdf




GenPrecis!

http://pharmatechsolutions.co/
GenPrecis® Precision Monitoring System

 
Designed to be the Most Accurate Home Monitoring System on the Market

This GenPrecis® Precise meter along with the GenPrecis® test strip will allow the diabetic to perform a most accurate and precise glucose test while automatically adjusting for hematocrit interference, the interference most often associated with less accurate glucose results.



New products link

http://www.decisiondiagnostics.co/
 

PetSure!®

 

GenAccord®

 

GenChoice!®

 

GenSure!®

 

GenUltimate!® Meter

 


 




Neither GenSure! nor GenPrecis! is available for sale or distribution in the U.S. or Puerto Rico.


 





GenPrecis!


"...we have created a panacea product that promises to provide the most accurate glucose results of all commercially available glucose

monitoring systems. GenPrecis!, in fact, is now performing as well as many hospital-based bedside chemistry analyzers.”

GenPrecis! is designed to exceed published performance standards for at-home glucose devices by as much as 50%, while operating in a

"portable package" small enough to fit comfortably in the hand of an 11 or 12-year-old, while providing glucose results to diabetics

for less than $.25 per strip."







DECISION DIAGNOSTICS' PANACEA GENPRECIS! PRODUCT MOVES INTO PRE-PRODUCTION, 1ST ROUND CLINICAL TRIALS TO BEGIN IN THE ~30 DAYS

Initial testing proves DECN’s GenPrecis! system is performing above and beyond published standards, looking toward becoming an industry Legacy in its own right!


Los Angeles, CA -- March 21, 2018 -- InvestorsHub NewsWire -- Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the new internationally launched GenSure! ("Feather") diabetes test strip, and the GenChoice! "Ladybug" diabetes test strip now in clinical trials.
Today, we are excited to discuss the progress and the successes we have had with our panacea system, GenPrecis!. We are pleased to report our progress is ahead of schedule and set for International launch in late spring 2018, a more precise date shall be announced in coming weeks.

Keith Berman, CEO of Decision Diagnostics, commented, "In the past 90 days we have finished the development of the GenPrecis! system proving to ourselves and our partners that we have created a panacea product that promises to provide the most accurate glucose results of all commercially available glucose monitoring systems. GenPrecis!, in fact, is now performing as well as many hospital-based bedside chemistry analyzers.”
GenPrecis! is designed to exceed published performance standards for at-home glucose devices by as much as 50%, while operating in a "portable package" small enough to fit comfortably in the hand of an 11 or 12-year-old, while providing glucose results to diabetics for less than $.25 per strip. "

The need for a product such as GenPrecis! has become even more critical and pronounced with continuous monitoring products entering the marketplace. GenPrecis! fills a demand vacuum by operating with greater precision , but also by providing innovative wireless data exchange, all in a small hand-held meter. In addition to our “25 cent” precise solution, we anticipate that GenPrecis! Precise meters will be provided to the diabetic free of charge.

Mr. Berman continued, "If we benchmark a static growth rate of at-home glucose solutions in the worldwide markets, DECN forecasts a 6% market share for GenPrecis!, by 2022. With the average usage of three test strips per day ($.75), we believe that GenPrecis!, could generate revenues in the low to mid 9-figures. Net profit margins are expected to be in excess of 20%.

Mr. Berman concluded, "As stated in late December, GenPrecis! has provided DECN with a major opportunity to become its own legacy. Our engineers were charged with the task of designing a product that will carve a technological gateway to the next decade and beyond. The company continues to believe that we will need a partner with deep pockets, international presence, and large worldwide sales forces to take on the challenge and the opportunities presented. Three of these potential partners have already found us and meetings have ensued."

ABOUT DECISION DIAGNOSTICS CORP.
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 6 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products will shortly compete on a worldwide scale with legacy manufacturers currently selling to 72+ percent of a $14.4 billion market.

Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of March 20, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
Joanne Broeders (305) 340-1000
info@decisiondiagnostics.com
www.pharmatechdirect.com

https://ih.advfn.com/p.php?pid=nmona&article=77000236





 Alltara™ Family of Products!

http://www.pharmatechsolutions.co/images/PTS_new_family_products.png

Alltara™ Family of Products!

PharmaTech is pleased to announce a new family of exclusive private label products that we have branded as Alltara!™. Unless otherwise noted, the Alltara!™ family of products will be available only to one large U.S. based entity with existing private label or house brand products.

Alltara!™ precis and Alltara!™ choice are both in development and not yet ready for sale

(Read In "DECN Announces..." below)

Hybrid Private Label Model

We have registered with the U.S. USPTO and the U.S. FDA two new product family names; Alltara!™ and Advant!™. These brands will become those licensed to big box retailers as their own exclusive private label. We anticipate registering more trade family names as our "big box" plan proceeds. The company is currently completing the private label packaging for the GenUltimate!™ product, now named Alltara!™ ultimate. This expansion is expected to be followed by Alltara!™ choice and then by Alltara!™ precis. First deliveries of Alltara!™ ultimate are expected in 2Q 2018. This brand will not be sold by any direct to patient distributors. First postings of product images, with disclaimers, if any, will be placed on the company's websites in coming days. The company will provide a full discussion of this business model in its 2017 Annual Report.

Mr. Berman concluded, "It is exhilarating when large big box retailers pursue our products for placement on their shelves. The years of litigation and struggle have been finally rewarded with the collapse of the retail barriers erected by J&J to our product placement in the retail marketplace. Now that those obstacles are crumbling, we intend to capitalize on the opportunity with our existing products and our eagerly anticipated bevy of new product introductions."

http://www.pharmatechsolutions.co/products.html


 


 

DECN ANNOUNCES 2018 BUSINESS FOCUS -- NEW PRODUCTS, CONCLUSION
 

TO J&J LITIGATION & NEW ADDITION OF HYBRID PRIVATE LABEL MODEL



http://www.nasdaq.com/press-release/decision-diagnostics-announces-2018-business-focus-through-the-introduction-of-new-products-20180103-00580

LOS ANGELES, CA / ACCESSWIRE / January 3, 2018 /Decision Diagnostics Corp. (OTC PINK:DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ ("Sunshine") diabetes test strip, the new internationally launched GenSure!™ ("Feather") diabetes test strip, and the clinical trial ready GenChoice!™ ("Ladybug") diabetes test strip, as well as three other unique test strips and meters in development, including our panacea strip and meter system the highly innovative GenPrecis!™ and its first collateral asset, our GenAccord!™ multiple-egress test strip. Today, DECN previews its plans and expected outcomes for 2018.

J&J Litigation

DECN has been locked in confrontational patent litigation with two divisions of Johnson & Johnson (JNJ), almost continuously, since September 2011. The company was victorious as a Defendant in the first three suits and received a payout at their conclusion. The current lawsuit positions two divisions of DECN as plaintiffs having filed suit against J&J for infringement of the company's patented test strip technology. As anticipated, J&J has employed the identical deceptive tactics and delaying strategies they embraced during the prior litigations. They failed to affect the final outcome in the past and it is expected that they will fail once again. The company's legal positions are strong and are supported by the rulings made by higher courts in the first three cases. If necessary, the company is fully prepared, both legally and financially, to litigate until J&J has exhausted their final appeal. However, the company believes that the strength of its position will ultimately drive a negotiated settlement.

Keith Berman, CEO of Decision Diagnostics Corp., commented, "J&J, through their superior resources and "scorched earth" legal strategy, has exacted heavy tolls on our business operations. However, through this adversity, the company has discovered its footing as a legitimate competitor in a highly regulated and heavily litigious environment. We are now fortified and fully prepared to successfully engage as we introduce new products and continue to expand our base of business."

New Product Introductions

2018 is expected to become a seminal year for DECN. It begins with the marketing of its launched GenSure!™ diabetic test strip, targeted for the patient population across the developing markets. The company will then, in rapid succession, introduce three new products, the GenChoice!™ test strip for worldwide distribution, GenPrecis!™ test strip and Precise meter, and the GenAccord!™ multiple-egress test strip that capitalizes on the GenPrecis!™ "full spread electro-chemistry technology." This intense activity begins January 15, 2018 with the global introduction of the GenSure!™ test strip. Following shortly thereafter, at the end of January 2018, the commencement of clinical trials for the GenChoice! test strip should culminate with the filing of 510K application filing for market clearance with the U.S. FDA in late February. International sales of GenChoice!™ are expected to begin in March 2018.

Additionally, the company intends to finalize its testing of the GenPrecis!™ test strip by January 28, and the GenPrecis!™ Precise meter by February 28. This GenPrecis!™ test strip is now compatible with two legacy meters sold internationally.

Mr. Berman continued, "Our one overriding goal has been to create a brand that is unique and superior to what the industry has thus far produced. DECN is not, and will never be, another uninspired producer of imitation products. We are committed to being creative, nimble and aggressive throughout our current and future product line."

Hybrid Private Label Model

We have registered with the U.S. USPTO and the U.S. FDA two new product family names; Alltara!™ and Advant!™. These brands will become those licensed to big box retailers as their own exclusive private label. We anticipate registering more trade family names as our "big box" plan proceeds. The company is currently completing the private label packaging for the GenUltimate!™ product, now named Alltara!™ ultimate. This expansion is expected to be followed by Alltara!™ choice and then by Alltara!™ precis. First deliveries of Alltara!™ ultimate are expected in 2Q 2018. This brand will not be sold by any direct to patient distributors. First postings of product images, with disclaimers, if any, will be placed on the company's websites in coming days. The company will provide a full discussion of this business model in its 2017 Annual Report.

Mr. Berman concluded, "It is exhilarating when large big box retailers pursue our products for placement on their shelves. The years of litigation and struggle have been finally rewarded with the collapse of the retail barriers erected by J&J to our product placement in the retail marketplace. Now that those obstacles are crumbling, we intend to capitalize on the opportunity with our existing products and our eagerly anticipated bevy of new product introductions."

ABOUT DECISION DIAGNOSTICS CORP.

Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.2 million diabetics worldwide. With new inspired technology already in the final stages of development, ready for market, or in final clinical trials, DECN products are already or set to compete on a worldwide scale with legacy manufacturers currently selling to 66%+ percent of a $12 billion market.

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of January 2, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.


From the Report From Quarter Ended September 30, 2017 filed November 14, 2017:

In June 2017 the company was contacted by a “big box” pharmacy chain, and in September 2017 by a large grocery chain, each wanting to exclusively enter into private label arrangements for our products. The company agreed to use its Alltara! brand name with the “big box” arrangement and will introduce this exclusive private label version of our GenUltimate!, GenChoice!, and GenPrecis! products, named Alltara Ultimate, Alltara Choice,and Alltara Precis respectively. In September 2017 the company filed for additional trademarks to facilitate the arrangement with the large grocer and others.
 
While the GenUltimate!, GenSure! and GenChoice! products fall into our current business model, that of making alternative products for legacy glucose meters, the GenPrecis! product is different. GenPrecis! will be a meter(s) and strip system, both of our own manufacture. We designed GenPrecis! for two specific markets, the Type1 diabetic market, and the Type 2 (adult on-set) diabetic market where the need for precision is paramount. The major feature of GenPrecis! will be its ability to provide diabetics with unapparelled precise glucose answers. GenPrecis will be built to correct for the largest mitigating factor in glucose monitoring, the correction of either more abundance or lack of abundance of red cells (hematocrit or HCT) in the diabetics’ blood. There will be two versions of the GenPrecis! meter, one designed primarily for children, specifically children attempting to live (close to) normal lives where their lives will be enhanced by an ability to maintain, through the human evolved GenPrecis! meter, 24/7electronic communication with physicians, care givers and parents. The second version of the GenPrecis! meter will allow Type 2 diabetics to monitor their glucose similarly to current methods, but with the previously mentioned unparalleled precision.

The company estimates, and has verified through a large marketing research firm, that GenPrecis! could eventually achieve a 6% worldwide market share. The higher part of that market share will be in the U.S. and Canada where the anticipated share will be 8.5%. To achieve this success/market share we have determined that heavily resourced partners are needed. The company envisions two partners, one to service the U.S. and a second to service the rest of the world. To that end, the company has chosen a large “big box” to partner with us in the U.S., and in Canada the U.S. “big box” Canadian subsidiary. Within the next 30 days, the exclusive private label versions of GenUltimate!, GenChoice! and GenPrecis! will be posted to the company’s web sites. Of course there are many tasks still to be accomplished, particularly with the live patient trials and the regulatory pre-market approvals required through the FDA, but the company is pleased with its choice of marketing “muscle.”

OTC Disclosure & News Service

 
Mar 21, 2018 DECN News: DECISION DIAGNOSTICS' PANACEA GENPRECIS! PRODUCT MOVES INTO PRE-PRODUCTION, 1ST ROUND CLINICAL TRIALS TO BEGIN IN THE ~30 DAYS
Mar 03, 2018 DECN News: Decision Diagnostics' Fundamental Genchoice! Test Strip Moves into Clinical Trials in Advance of 510K Filing with FD
Jan 03, 2018 DECN News: DECN ANNOUNCES 2018 BUSINESS FOCUS -- NEW PRODUCTS, CONCLUSION TO J&J LITIGATION & NEW ADDITION OF HYBRID PRIVATE LABEL MODEL

Nov 14, 2017Quarterly Report - OTC PINK QUARTERLY REPORT FOR 3Q 2017
Nov 14, 2017Management Discussion and Analysis - OTC PINK QUARTERLY REPORT FOR 3Q 2017
Nov 14, 2017Supplemental Information - OTC PINK QUARTERLY REPORT 3Q 2017
May 15, 2017 Quarterly Report - OTC PINK QUARTERLY REPORT 1Q2017 BALANCE SHEET_FOOTNOTES & STATEMENTS OF EQUITY AND CASH FLOWS    
May 15, 2017 Management Discussion and Analysis - OTC PINK QUARTERLY REPORT 1Q2017 MANAGEMENTS DISCUSSION AND ANALYSIS    
May 15, 2017 Supplemental Information - OTC PINK QUARTERLY REPORT 1Q2017 SUPPLEMENTAL DISCLOSURE INFORMATION    
Mar 31, 2017 Management Discussion and Analysis - OTC PINK ANNUAL REPORT 2016_MANAGEMENTS' DISCUSSION & ANALYSIS    
Mar 31, 2017 Annual Report - OTC PINK 2016 ANNUAL REPORT__BALANCE SHEET FOOTNOTES & SCHEDULES    
Mar 30, 2017 Supplemental Information - OTC MARKETS 2016 ANNUAL REPORT_SUPPLEMENTAL DISCLOSURE INFORMATION    
Mar 30, 2017 Attorney Letter with Respect to Current Information - OPINION LETTER FROM ATTORNEY THOMAS COOK: CURRENT INFORMATION    
Nov 15, 2016 Supplemental Information - OTC PINK CURRENT 3Q 2016 SUPPLEMENTAL DISCLOSURE INFORMATION    
Nov 15, 2016 Management Discussion and Analysis - OTC PINK CURRENT 3Q 2016 MANAGEMENTS' DISCUSSION & ANALYSIS    
Nov 15, 2016 Quarterly Report - OTC PINK CURRENT 3Q 2016 BALANCE SHEET_P&L & STATEMENTS OF EQUITY & CASH FLOWS
 
       
       
   
 
 

Recent Updates


Keep track of the latest developments:

Pharma Tech Solutions, Inc. et al v. Lifescan, Inc. et al


https://www.pacermonitor.com/public/case/10960512/Pharma_Tech_Solutions,_Inc_et_al_v_Lifescan,_Inc_et_al

DECN Subsidiaries File Amended Complaint Against Jonhson & Johnson Alleging Infringement Under Authoritative Doctrine of Equivalents (May 4)


DECN Wins Opening Round in Innovatory Patent Infringement Suit Against Industry Goliath Johnson & Johnson (Mar 21)





HIGHLIGHTS FROM 1st QUARTER 2017


https://www.otcmarkets.com/stock/DECN/filings

 The GenSure! product has completed its clinical
trials, and is currently in registration and is seeking a CE mark in the EU, and will be launched in July 2017. We have
identified International distributors for this product..


In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a
new product which the company will call GenPrecis!. This product, when completed, will represent a major
improvement in diabetic glucose monitoring. The GenPrecis! system will be the first of its kind +/- 10% system.
Current ISO (2013) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard,
whereby the meter and strip must be within +/- 15% in repeated samplings 95% of the time. GenUltimate! and
GenChoice! are +/- 15% test strips, but in each case 97+% of the time in repeated samplings. GenPrecis! is designed
to meet the written standards of the ISO and FDA at +/- 10%, 95% of the time – effectively setting a new standard.
The company has been funding the development of this system product, and a test strip only derivative version. The
system product will be ready for testing in September 2017 and will be registered for International sale in November
2017. However, the natural market for this product will be the U.S, and Canada where precision standards are higher
for new products.

The company entered into two international agreements in the latter part of 2016. The first agreement,
executed through the company’s exclusive Korean agent, allows for delivery of the GenUltimate! product in quantity
to the Korean market. As of this writing, the Korean partners have ordered and paid for over 65,000 pieces (units) of
GenUltimate! Another almost 20,000 pieces (units) are on order for late June 2017. The company’s second
international agreement is through a South American financier who has businesses in Bolivia and Spain. This group
has placed a single two-year (term) order for approximately $17 million in GenUltimate! product, GenUltimate!
meters and the company’s new (2017) Firefly! Lancets. Almost 11,000 pieces (units) of GenUltimate!, 3,000
GenUltimate! meters and cases of lancets have been delivered to Bolivia. In addition, the South America financier has
funded the company’s regulatory applications (through a Spanish pharmaceutical company) with the EU, to gain “CE”
marking for its GenUltimate! and GenSure! products (and later in 2017 the company’s GenChoice! and GenPrecis!
Products) in return for the Spanish distribution rights to these two products. And lastly, the South American financier
has notified the company that he and those closely associated with him wished to subscribe to a $3.25 million to $5.0
million capital investment in the company. As of this writing the company has not concluded this capital investment,
at its choice, but recently received a signed and dated a Subscription Agreement for this upcoming investment from
the financier. Among the many terms in this investment, the South American financier will not be able to convert and
sell any securities that underlie the investment vehicle for 36 months from the time of the investment.


On May 5, 2017 the company was contacted by a worldwide private label manufacturer and distributor for
the purposes of worldwide distribution of our products under their brand(s). We are in discussions with this entity
currently. This company has headquarters in the U.S. (Midwest) and France.


The company’s stock currently trades on the OTCMarkets OTC Pink Current tier of the market. The company’s shares are
DTC eligible. On May 12, 2015 the company made an application for a tier change to the OTCQX (common) tier. When the company’s
common stock fell in price beneath the $.10 threshold, and when our sponsoring broker shuttered his operation, our application went
into hiatus. Subsequently, we have been in contact with OTCMarkets and we plan to revive our application after we complete an M&A
transaction. To that end we have agreed to work with an M&A partner, a current SEC filer with a large shareholder base. We have
executed a Preliminary Agreement and are in the final stages of completing a Definitive Agreement. We anticipate closing this
transaction late in the second quarter 2017. Subsequently, the company received direct communication from OTCMarkets concerning
a new uplist program offered, beginning May 18, 2017, whereby the company might uplist within the OTCMarkets tiers as a Current
Alternative reporting company and filer. Regardless of which of these uplist paths the company’s Board of Directors decides regarding
the OTCMarkets programs, we plan to continue working through the M&A plan now in progress

At a hearing in March 2017 the Federal judge denied Lifescan’s Motion to Dismiss, granted the company’s request to allege the Doctrine
of Equivalents and set dates beginning in early April 2017 and ending in early November 2017 that could set the stage for a ruling.
Sometime in June 2017 the company expects to amend its suit a second time and name other “infringers” as well as adding additional
counts to the suit. Federal rules for patent infringement suits have changed, and these suits are now adjudicated over an 18-24 month
period. The trial judge’s ruling in mid-March seems to foot with this schedule. In addition, if the schedule set by the judge does not end
the litigation, there are five scheduled Mediations in front of a Federal Judge Magistrate pushing the process along. The company
amended its suit in April 2017, alleging patent infringement on behalf of the J&J entities under the Doctrine of Equivalents. The J&J
entities answered the amended complaint later in April, and the (next step) expert testimony has begun.


On May 5, 2017 the company was contacted by a worldwide private label manufacturer and distributor for the purposes of
worldwide distribution of our products under their brand(s). We are in discussions with this entity currently. This company has
headquarters in the U.S. (Midwest) and France.

As a part of the company’s strategic plans, we have applied (to register) for seven Trademarks with the USPTO. The company’s
Genstrip product is a registered Trademark of Shasta Technologies LLC. Our applications were filed with the USPTO in 1Q and 2Q
2015 and 3Q 2016. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and
the establishment of a family of Marks associated with our company and its place in our industry. As December 31, 2016 the company
has received registration confirmation from the USPTO for the following Marks:
“Alltara!”
“GenUltimate!”
“GenSure!”
“GenChoice!”
“GenAccord!”
“GenCambre!”
“Firefly!”
In early May 2017 the company filed for a mark on its GenPrecis! Product.

 

 



 

DECN Press Releases

May 2017

DECN Subsidiaries File Amended Complaint Against Jonhson & Johnson Alleging Infringement Under Authoritative Doctrine of Equivalents (May 4)

March 2017

DECN Wins Opening Round in Innovatory Patent Infringement Suit Against Industry Goliath Johnson & Johnson (Mar 21)

DECN Victorious as U.S. Supreme Court Rejects Johnson & Johnson Appeal Ending 65 Month Patent Infringement Litigation (Mar 1)

December 2016

DECN Increases Manufacturing Capacity, Opens International Markets for Popular GenUltimate! (Dec 1)

November 2016

DECN Opens International Markets for Popular Genultimate!, Increases Factory Capacity (Nov 30)

August 2016

DECN Litigation Victory Against Johnson + Johnson, Launches Foothold in On-Line Retail Markets for Its Popular "Gen" Products (Aug 23)

July 2016

Decision Diagnostics Ends Plans and Communications With Tauriga Sciences, Inc. Concerning Possible Reverse Merger Transaction (Jul 1)

June 2016

Decision Diagnostics Emerges Victorious in End to Acrimonious Patent Litigation With Divisions of Johnson + Johnson (Jun 2)

May 2016

Decision Diagnostics Nears Positive Ending of Its California Patent and Trademark Infringement Litigation With Divisions of Johnson + Johnson (May 12)

Download Available: Federal Circuit Court Order Denying Appeal made by Lifescan and Johnson & Johnson and imposing mandate on May 17, 2016

Download Available: Schedule Report for GenStrip50 TV Advertising (May 1)

April 2016

Download Available: Schedule Report for GenStrip50 TV Advertising (Apr 25)

Forbes Article: David-Goliath Fight Over Glucose Tests For Diabetics Hits Boiling Point (Apr 20)

Decision Diagnostics Engages Retail Monster LLC to Procure Big Box Retailers for Company's GenUltimate Product (Apr 14)

March 2016

Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions (Mar 16)

DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement (Mar 14)

February 2016

Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson (Feb 9)

January 2016

DECN Assesses Its Recent Landmark Legal Victories Over Diabetes Division Of Johnson & Johnson (Jan 28)

Decision Diagnostics Wins Federal Appeals Court Victory, Ruling Affirms J&J Division's Loss of US Patent No. 7,250,105 (Jan 21)

We Win! United States Court of Appeals for the Federal Circuit - Opinion Filed for LifeScan Scotland, Ltd. v. Pharmatech Solutions, Inc. (Jan 20)

(Return to Top)

December 2015

Download Available: United States Court of Appeals for the Federal Circuit - Oral Argument Recording for LifeScan Scotland, Ltd. v. Pharmatech Solutions, Inc. (Dec 18)

June 2015

Decision Diagnostics Completes Investment in Korean R+D and Contract Manufacturing Partner (Jun 15)

Decision Diagnostics Executes Broad Manufacturing and R+D Agreement With Korean Manufacturer (Jun 4)

May 2015

Decision Diagnostics States Johnson & Johnson Division Offers Partial Surrender in Long Running Patent Battle (May 19)

Decision Diagnostics Files Application for Uplisting to OTCMarkets OTCQX (May 12)

April 2015

Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case (Apr 21)

U.S. Solicitor General Intervenes Against Johnson & Johnson in DECN's Long Running Patent Battle Over GenStrip 50 (Apr 14)

March 2015

Johnson & Johnson Division Attempts Final Appeal in Effort to Overturn Multiple USPTO Decisions Issued in DECN's Favor (Mar 31)

Decision Diagnostics Rejects Settlement Offers From J&J/Lifescan, Company's Prosecutions of Court Bond and Anti-Trust Actions Now Move On (Mar 4)

January 2015

Updated TV Commercial Fulfillment (Jan 20)

DECN Plans New Legal Challenge After LifeScan (J&J) Admits to Using Sworn Testimony From Expert With Falsified Credentials (Jan 14)

(Return to Top)

December 2014

DECN Initiates End Game Strategy For Litigation With Division Of Johnson & Johnson (Dec 3)

November 2014

DECN's Subsidiary Initiates First In Industry Social Media Marketing Campaign For Genstrip50 (Nov 5)

August 2014

David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling (Aug 11)

David Beats Goliath in Patent Rematch (Aug 7)

June 2014

DECN's Pharma Tech Subsidiary Places Significant Order for 50,000 Units of Genstrip 50 for Immediate Delivery to Select U.S. and International Distributors (Jun 3)

May 2014

Decision Diagnostics Corp. Subsidiary Pharma Tech Enters International Markets With Conformité Européenne (CE) Mark Submission (May 29)

GenStrip Opportunity Expands Under Full Control of DECN's PharmaTech Division (May 1)

April 2014

Decision Diagnostics Responds to Shasta Technologies FDA Safety Warning Letter (Apr 30)

Decision Diagnostics Subsidiary Acquires GenStrip (Apr 16)

March 2014

Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "Monolith"(Mar 31)

Decision Diagnostics Announces Engagement of Mark Krakauer to Head Up Genstrip Private Label Sales Efforts (Mar 11)

TV Commercials Fulfillment #3 (Mar 4)

February 2014

TV Commercials Fulfillment #2 (Feb 26)

Decision Diagnostics Announces Agreement for Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson (Feb 18)

TV Commercials Fulfillment #1 (Feb 15)

January 2014

Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "A Winter Patchwork" (Jan 15)

(Return to Top)

December 2013

Decision Diagnostics Closes $12.5 Million (Non-Dilutive) Credit Facility With Division of Platinum Credit Management (Dec 19)

Decision Diagnostics Starts its Turnaround (Dec 17)

Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J Division (Dec 17)

Mandate from Federal Appeals Court (.pdf) (Dec 11)

Decision Diagnostics' Board Votes to Uplist to OTC QX (Dec 10)

November 2013

Decision Diagnostics Takes Victory In Major Case Ruling (Nov 11)

Diabetes: J&J loses a round in glucose testing battle with Shasta (Nov 7)

Decision Diagnostics On Track For Growth And Increased Revenues (Nov 7)

DECN And Pharma Tech Solutions Receive Anticipated Ruling From The U.S. Federal Circuit Court Of Appeals, Reversing A Ruling By Lower Court Judge (Nov 5)

DECN Wins Only Case That Matters in Federal Circuit Court (.pdf) (Nov 4)

October 2013

Well Ahead Of Schedule, Decision Diagnostic's Pharma Tech Division Completes First Major Shipments Of Its Popular Genstrip Test Strip (Oct 31)

Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DECN’s GenStrip Roll-Out Plan (Oct 29)

Decision Diagnostics Could Be The New Vringo (Oct 24)

Recognized Healthcare And Financial Publications Acknowledge Decision Diagnostics’ GenStrip Market Potential (Oct 22)

DECN Set To Climb As GenStrip Enters Blood Glucose Monitoring Market With First Shipments (Oct 22)

Decision Diagnostic Blood Glucose Test Strip Technology Enters Market with Genstrip (Oct 22)

Court Ruling for Decision Diagnostics Order Staying Proceedings (.pdf) (Oct 9)

Decision Diagnostics' Pharma Tech Division Schedules Shipments For Its Popular GenStrip Test Strip (Oct 3)

Decision Diagnostics' Pharma Tech Division Schedules Large Order Shipments for Its Popular GenStrip Test Strip (Oct 1)

September 2013

David And Goliath Case Offers A Surprising Opportunity (Sep 26)

J&J feels Decision Diagnostics' sting in glucose strip patent fight (Sep 12)

J&J's Blood Sugar Testing Patent Spat Turns Sour (Sep 12)

J&J Seeks Court Aid To Protect Its Glucose Monitoring Test (Sep 11)

Decision Diagnostics Corp. Announces Completion and Airing of Its New Genstrip Video Titled "A Patchwork of Life" (Sep 10)

Decision Diagnostic's GenStrip Could Change the Blood Glucose Market (Sep 1)

August 2013

Court's Ruling on PharmaTech's Motion for Contempt (Aug 28)

GenStrip™ and USPTO Ruling (Aug 15)

Decision Diagnostics Subsidiary Makes Move and Sues Two Johnson and Johnson Divisions for False Advertising in Ongoing Battle (Aug 1)

May 2013

DECN Steps Into Role of White Knight by Offering Strategic Version of GenStrip™ Exclusively for Medicare Competitive Bidding Program (May 29)


  • Decision Diagnostics Corp. is saddened to announce the sudden passing of our long-time friend and Computer and Information Systems Manager, Mr. Alan B Binder (May 10)

April 2013

Decision Diagnostics Corp. and Its Subsidary PharmaTech Solutions Seek to End Pharma Giant's Alleged Restraint of Trade Tactics (Apr 5)

Decision Diagnostics Corp. and Its Subsidiary PharmaTech Solutions, Inc. Sue Johnson & Johnson Division LifeScan, Inc. and LifeScan Scotland Ltd. for Antitrust Violations (Apr 4)

March 2013

J&J Faces Potentially Disrupting Competition In Its Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfit (Mar 11)

January 2013

FDA Review - Decision Summary (Jan 2)

FDA 510(k) Premarket Notification (Jan 2)

(Return to Top)

December 2012

FDA 510(K) Clearance Letter (Dec 5)

Opportunity and Market for Decision Diagnostics (OTCBB:DECN) Shasta GenStrip®; at home diagnostic for testing blood glucose (Dec 4)

November 2012

Medical Technology Stock Q&A with Decision Diagnostics (Nov 28)

Medical Technology Stock Decision Diagnostics Lead Product Shasta Genstrip Positions for at-home testing of Blood Glucose Market (Nov 21)

Decision Diagnostics Set to Become Force in at-home testing of blood glucose, estimated $22.5 Billion Worldwide (Nov 16)

January 2012

Decision Diagnostics Corp. is saddened to announce the passing of our friend and financial guidance advisor, Mr. William N. Walling, Jr. (Jan 18)

Medical IT and Diagnostic Product Company Decision Diagnostics Announces Patent Enforcement Strategy for Their Smart Phone Based EMR Technology (Jan 11)

(Return to Top)

December 2011

Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy (Dec 27)

Decision Diagnostic Corp. (Formerly InstaCare) Announces 10% Stock Dividend (Dec 6)

Instacare Changes Name to Decision Diagnostics Corp.; Will Apply for Nasdaq Bx Exchange Listing (Dec 1)

May 2011

Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate (May 11)

InstaCare Corp. Receives Second Confidential Merger Offer From NASDAQ Traded Company (May 9)

April 2011

InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market (Apr 18)

March 2011

 Download Hudson Securities - OTC Bulletin Board (.pdf) (Mar 11)

MD@Detail coming soon!

InstaCare Announces Ready for Market MD@Detail Mobile Health Media System for Pharmaceutical e-Detailing (Mar 10)

InstaCare Extends MD@Hand & MD@Work Mobile EMR/EHR Technology to Smart Pad Systems (Mar 3)

InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA (Mar 2)

February 2011

InstaCare Files Full Utility Patent for MD@Hand & MD@Work Technologies (Feb 28)

(Return to Top)

June 2010

InstaCare Subsidiary Inks 5-Year Exclusive Pact for Distribution of Proprietary Diabetes Test Strip Into $9.8 Billion Testing Market (Jun 24)

InstaCare Retains Martin E. Janis & Company, Inc. to Launch Nationwide Comprehensive IR/PR Program(Jun 3)

March 2010

Instacare Corp. Files Patent Application for its MD@Hand Cell Phone Centric Technologies (Mar 2)

February 2010

instaCare Corp. Announces Launch of Infomercial Marketing Strategy (Feb 2)

January 2010

Download Available: Instacare Corp. States Conference Call on January 27 is a Success - Click here to download Conference Call (.mp3) (Jan 27)

Instacare Corp. Announces Details of Conference Call on January 27 (Jan 25)

instaCare Corp. Finalizes MD@Hand Parallel Marketing Strategy (Jan 25)

DownLoad Available: Download Chairman's Letter to Stockholders(.pdf) (Jan 20)

instaCare Corp. Elects William Lyons to Its Board of Directors (Jan 14)

instaCare Corp. Finalizes MD@Hand Parallel Marketing Strategy (Jan 12)

Instacare Corp. to Host Shareholder Conference Call on January 27, 2010 to Discuss Recent Events (Jan 4)

(Return to Top)

December 2009

Instacare Corp. Board of Directors Sets Growth Plans for 2010 (Dec 17)

Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products (Dec 3)

November 2009

instaCare in Renewal and Increase of its $2 Million Monthly Revolving Credit Facility With Centurion Credit Resources, LLC (Nov 30)

ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes (Nov 23)

instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters (Nov 18)

(Return to Top)

May 2008

InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 (May 21)

September 2007

InstaCare Corp. Reviewing M&A Plans (Sep 26)

April 2007

Instacare Corp. Announces Expanded Product Lines, Group Vendor Agreements and Enhanced Customer Base (Apr 04)

July 2006

InstaCare Corp. in Contract Deliberations With Mexican Government Health Institute ISSSTE for E-Health Implementation Pact (Jul 20)

InstaCare Receives Enhanced Targets and Rating From Wasserman Morris in Latest Research Report (Jul 17)

May 2006

instaCare Corp. to Hold Conference Call May 25, 2006 (May 23)

September 2005

instaCare Corp. Comments on Recent Significant News Concerning the Efficacy of Cost Saving Wireless Technologies in Healthcare (Sep 13)

 

 

Cannabis Report
Lithium
DECN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DECN News: Registration a Offering Under the Securities Act of 1933 (1-a) 08/01/2018 08:06:42 AM
DECN News: Decision Diagnostics (DECN) Contemplates Additional Legal Actions Against Longtime Adversary Johnson & Johnson (JNJ) 04/18/2018 09:51:34 AM
DECN News: DECISION DIAGNOSTICS DISCUSSES CULMINATION OF PATENT CASE AGAINST J&J BASED ON THE FEDERAL DOCTRINE OF EQUIVALENTS 03/27/2018 03:05:54 PM
DECN News: DECISION DIAGNOSTICS' PANACEA GENPRECIS! PRODUCT MOVES INTO PRE-PRODUCTION, 1ST ROUND CLINICAL TRIALS TO BEGIN IN THE ~30 DAYS 03/21/2018 09:40:00 AM
DECN News: Decision Diagnostics' Fundamental Genchoice! Test Strip Moves into Clinical Trials in Advance of 510K Filing with FDA 03/13/2018 09:50:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#50852  Sticky Note DECN Announces Significant Updates For Products And Programs nonsequetor 08/14/18 11:24:17 AM
#50548  Sticky Note Now that big bad johnson and Johnson is plutoniumimplosion 07/26/18 10:06:44 AM
#50961   "My family lost quite a bit of dough plutoniumimplosion 08/17/18 11:09:40 AM
#50960   "My family lost quite a bit of dough zoran 08/17/18 11:04:07 AM
#50959   I have every right to comment on DECN plutoniumimplosion 08/17/18 10:57:27 AM
#50958   Dude, your the one who initiated caused the Johnny_C 08/17/18 10:51:53 AM
#50957   Oh. Contact the company and post your results. plutoniumimplosion 08/17/18 10:15:56 AM
#50956   Show proof where Bozo Berman sues auditor for Johnny_C 08/17/18 10:10:49 AM
#50955   I told you last year to tell Bozo plutoniumimplosion 08/17/18 10:04:33 AM
#50954   Maybe they can go to Retail Monster, remember Johnny_C 08/17/18 10:03:27 AM
#50953   Why has GenUltimate! not been able to be Hopefull17 08/17/18 09:46:56 AM
#50952   Yeah. Get to it. Have your Johnny_C 08/17/18 07:59:43 AM
#50951   Rarely are your statements facts. Most are opinions, Jelly Bean 08/17/18 07:26:27 AM
#50950   Will be trading under a penny soon. scottsmith 08/16/18 09:30:26 PM
#50949   This stock is a dog, even I never seifer1975 08/16/18 08:59:49 PM
#50948   My statements are all facts, and are easily plutoniumimplosion 08/16/18 08:53:20 PM
#50947   LOL, the only one who lies is Bozo Johnny_C 08/16/18 08:43:40 PM
#50946   Hope they helped you as 3 weeks sounds plutoniumimplosion 08/16/18 07:23:37 PM
#50945   "Just logged on after three weeks away" zoran 08/16/18 07:16:43 PM
#50944   Anyone like to guess the ONLY poster here Alydyr 08/16/18 06:52:21 PM
#50943   Everyone thanks you for finding the typos and Alydyr 08/16/18 06:48:22 PM
#50942   Bozo Berman has made a ton of money plutoniumimplosion 08/16/18 03:08:31 PM
#50941   Bozo Berman has made a ton of money Johnny_C 08/16/18 02:43:02 PM
#50940   If there is a point I am at plutoniumimplosion 08/16/18 02:35:51 PM
#50939   I never stated I made money in taug. Johnny_C 08/16/18 02:34:03 PM
#50938   Finally, you are correct! Good Job! Hopefull17 08/16/18 02:25:30 PM
#50937   "Shareholders will seek revenge on him, IMO!" zoran 08/16/18 01:58:20 PM
#50936   So let me get this straight.... zoran 08/16/18 01:49:23 PM
#50935   Doesn't seem the DECN BRAIN TRUST is LOVED plutoniumimplosion 08/16/18 01:49:05 PM
#50932   This is a DECN Board - STOP trying plutoniumimplosion 08/16/18 01:33:16 PM
#50931   This is a DECN Board - STOP trying Hopefull17 08/16/18 01:13:44 PM
#50929   that way Bozo Berman can wipe out plutoniumimplosion 08/16/18 12:29:12 PM
#50928   Of course there will be another huge reverse Johnny_C 08/16/18 11:47:47 AM
#50927   Why would I do that, the potential here Johnny_C 08/16/18 11:46:34 AM
#50926   Get ready for a future reverse split again. plutoniumimplosion 08/16/18 10:40:39 AM
#50925   Bozo Berman and management have created hundreds of Johnny_C 08/16/18 10:38:32 AM
#50924   Sounds like sour grapes to me. plutoniumimplosion 08/16/18 10:14:40 AM
#50923   "Since the end of 2016, the stock market zoran 08/16/18 09:39:56 AM
#50922   Stay tuned as to enforcement action plutoniumimplosion 08/16/18 09:14:32 AM
#50921   Proof is that NO 8-K was filed. Stay Johnny_C 08/16/18 09:07:04 AM
#50920   Proof is that NO 8-K was filed. Stay Johnny_C 08/16/18 09:06:58 AM
#50919   They concealed this fact to shareholders, lied about plutoniumimplosion 08/16/18 09:01:15 AM
#50918   Bozo Berman and the slimeballs that were and Johnny_C 08/16/18 08:39:46 AM
#50917   In yesterdays PR, you will see Keith M Cakes10 08/16/18 08:04:31 AM
#50916   Complete lack of fiduciary responsibility. plutoniumimplosion 08/16/18 06:50:24 AM
#50915   Now the latest from the CEO is that Friendofbmk 08/16/18 12:33:30 AM
#50914   In yesterdays PR, you will see Keith M Friendofbmk 08/16/18 12:28:36 AM
#50912   IMO, DECN Q-reports and PR's are replete with plutoniumimplosion 08/15/18 02:22:44 PM
#50911   IMO, DECN Q-reports and PR's are replete with Hopefull17 08/15/18 01:38:25 PM
#50910   Capacity....hmmm. Interesting choice of a word but whatever zoran 08/15/18 12:53:28 PM
#50909   Yesterday's PR was AN event (isolated, it now Hopefull17 08/15/18 12:49:36 PM
#50908   Don't worry, Zoran .... it was not you! Hopefull17 08/15/18 12:43:57 PM
PostSubject